Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

Pfizer stock has suffered as demand for the company’s top selling coronavirus products declined. The pharma giant has reached an important transition point. Right now, as an investor, you may be ...